AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories
All
|
Back to Blog
Risk Based Monitoring (RBM) is a clinical trial-monitoring technique that fulfills regulatory requirements but moves away from 100% source data verification (SDV) of patient data. It employs various tools, platforms and dashboards to identify signals, which indicate potential issues with (for example) trial conduct, safety, data integrity, compliance and enrolment.
What The Market Looks Like? The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3%. Based on the component, the RBM software market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to can be attributed to the increasing R&D expenditure in the life science and clinical research industries, an increasing number of clinical trials, and rising customer base. The pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429 Key Factors Driving Growth in RBM Software Market: 1. Cost and time efficiency of RBM solutions 2. Rising number of clinical trials 3. Increasing government funding and grants to support clinical trials 4. Increased outsourcing of clinical trial processes to CROs Geographical Growth Analysis of Risk-based Monitoring Software Market: The Asia Pacific market is expected to grow at the highest CAGR in the forecast period. This growth can be attributed to increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, low operating costs for conducting clinical trials, shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region. Read more: https://www.marketsandmarkets.com/Market-Reports/risk-based-monitoring-software-market-102112429.html
0 Comments
read more
Back to Blog
Healthcare Business Intelligence (BI) Market Worth USD 8.9 Billion Reshaping The Healthcare Industry5/21/2020 Healthcare business intelligence is the process by which large scale data from the massive healthcare industry can be collected and refined into actionable insights from key healthcare areas like costs, pharmaceuticals, clinical data, and patient behaviour.
The study involved four major activities to estimate the current size of the market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. What the market looks like? The healthcare business intelligence (BI) market is expected to reach USD 8.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 15.3%. On the basis of component, the healthcare BI market is segmented into platforms, software, and services. In 2018, the healthcare business intelligence platforms segment are expected to account for the largest share of the market. The large share of this market segment is mainly driven by the increasing requirement for customized BI solutions catering to individual requirements of organizations and allowing them the flexibility to build and integrate BI solutions into existing healthcare business applications for higher efficiency and reduced costs. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252368925 Key Factors Driving Market Growth: 1. Adoption of Data-Driven Decision-Making 2. Implementation of Government Initiatives to Increase EHR Adoption 3. Growing Pressure to Curb Healthcare Spending and Improve Patient Outcomes 4. Big Data in Healthcare 5. Increasing Number of Patient Registries 6. Advanced Analytics Enhancing Traditional Bi 7. Growing Demand for Cloud-Based Healthcare BI Solutions Key Players in Healthcare Business Intelligence Market: The market is highly competitive in nature, with several big as well as emerging players. Prominent players in this market include Microsoft (US), IBM (US), Oracle (US), SAP SE (Germany), SAS Institute Inc. (US), Tableau Software (US), MicroStrategy Incorporated (US), QlikTech International AB (US).
Back to Blog
Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cost, and easy-to-use radiotherapy products with improved and precise radiation dose delivery to offer increased efficiency in targeting tumors. The advancement from 2D to 3D conformal radiotherapy with real-time imaging has enabled high conformity of radiation to the target (with minimal exposure to normal tissue) and dose escalation with improved tumor control.
What the market looks like? The radiotherapy market is projected to grow from an estimated USD 5.6 billion in 2018 to USD 6.8 billion by 2023, at a CAGR of 4.1%. Based on type, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic radiotherapy. The external beam radiotherapy segment is expected to grow at the highest CAGR during the forecast period. Growth in this segment can primarily be attributed to the reduced risk of radiation exposure in external beam radiotherapy and the increased precision and accuracy of tumor targeting in this therapy. Download PDF Brochure: Radiotherapy Market What drives the market? The growth of the global market for Radiotherapy is primarily influenced by the following factors: 1. Technological Advancements 2. Rising Prevalence of Cancer 3. Increasing Number of Conferences and Symposia Focusing on Spreading Awareness About the Benefits of Radiotherapy 4. Growing Use of Particle Therapy for Cancer Treatment 5. Emerging Markets The emerging markets, growing government and private investments to meet the increasing demand for cancer treatment, and the improving reimbursement scenario are expected to present a wide range of growth opportunities for market players. Read more about Radiotherapy Market: https://www.marketsandmarkets.com/Market-Reports/radiotherapy-monitoring-devices-market-567.html
Back to Blog
Growth in the mass spectrometry market is primarily driven by factors such as government initiatives for pollution control and environmental testing, increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety, growing focus on the quality of food products, increase in crude and shale gas production, and technological advancements in mass spectrometers.
The mass spectrometry market is expected to grow from USD 4.6 billion in 2019 to USD 6.3 billion by 2024, at a CAGR of 6.7%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=437 Pharmaceutical & Biotechnology applications held the largest share of the mass spectrometry market: Mass spectrometry is widely used for accurate analysis of small as well as large molecules in pharmaceuticals, forensic & clinical research, and other areas. The mass spectrometry applications market is segmented into pharmaceutical & biotechnology applications, environmental testing, food & beverage testing, petrochemical applications, and other applications. The pharmaceutical & biotechnology applications segment held the largest share of the market in 2019, a trend that is expected to continue during the forecast period. The large share of this segment can be attributed to the rise in demand for pharmaceutical biosimilars, phytopharmaceuticals, and regenerative medicine. North America is expected to hold a dominant share in the mass spectrometry market during the forecast period: North America held the largest share of the market in 2018 and is projected to continue to do so during the forecast period. Factors such as the growing funding for research and government initiatives in the US, widespread usage of mass spectrometry in the metabolomics and petroleum sector, and CFI funding towards mass spectrometry projects in Canada are driving the North American market. Get In-Depth Analysis of How COVID-19 is Impacting The Global Mass Spectrometry Market: 1. Covid Impact on Mass Spectrometry Market, growth/decline in product type/use cases of Mass Spectrometry Market due to cascaded impact of Covid on Extended Ecosystem. 2. How top 50 companies in Mass Spectrometry Market are making rapid shifts in their strategies. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=437 Key Players: The major vendors in the mass spectrometry industry market include SCIEX (US), Agilent Technologies (US), Thermo Fisher Scientific (US), Waters Corporation (US), and Shimadzu Corporation (Japan). These leading players offer an expansive product portfolio for mass spectrometers and have a broad geographic presence.
Back to Blog
What are the key factors driving growth in global Molecular Spectroscopy Market?
The growth of molecular spectroscopy market is majorly driven by food safety concerns, the growth of the pharmaceutical and biotechnology industry, technological advancements in molecular spectroscopy and application of molecular spectroscopy in environmental screening. However, the high cost of equipment is likely to restrain the growth of the market during the forecast period. How global molecular spectroscopy industry will expand in coming years? The global molecular spectroscopy market is expected to reach USD 6.85 billion by 2022 from USD 4.98 billion in 2017, at a CAGR of 6.6%. The Pharmaceutical Application to Dominate The Industry: Based on application, the molecular spectroscopy market is segmented into pharmaceutical applications, environmental testing, food and beverage testing, biotechnology and biopharmaceutical application, academic research and other applications. During the forecast period, the pharmaceutical application is expected to grow at the highest CAGR. This growth is mainly due to the growing importance of molecular spectroscopy in various stages of drug development and increasing R&D in pharmaceutical industries. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=50034395 The Objective of Research is as Follows: 1. To define, describe, and forecast the global molecular spectroscopy market on the basis of product, application, end user, and region. 2. To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities and industry-specific challenges). 3. To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market. 4. To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for the market leaders. 5. To forecast the size of the market with respect to five regions: North America, Europe, Asia Pacific, and the Rest of the world. Regional Analysis: Asia Pacific to witness the highest growth during the forecast period Asia Pacific is expected to grow at the highest CAGR in the global molecular spectroscopy market during the forecast period of 2017–2022. Thriving biotechnology market in China, growing focus on environmental protection, growing biomedical and medical research in Japan, and rising food safety concerns in India are expected to drive market growth during the forecast period. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=50034395 Key Players: Bruker (US), Thermo Fisher Scientific, Inc. (U.S), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Danaher Corporation (US), ABB (Switzerland), Merck KGaA (Germany), JEOL Ltd. (Japan), FOSS (Denmark), JASCO, Inc. (US), and HORIBA Ltd. (US) |